CCR6 and hepatocellular carcinoma: TAMs abolish local immune surveillance by directly suppressing T‐cell activities through the secretion of immunosuppressive factors such as arginase 1 and IL10.[16] Recent studies have revealed that TAM‐derived CCL20 promotes CCR6+ Treg infiltration, potentially contributing to resistance to anti‐PD‐L1 therapy in hepatocellular carcinoma.[6d] Recent studies have also shown that various biological processes in immune cells, including macrophages, are influenced by RNA modifications.